FTY720 + Oral Corticosteroid
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
Conditions
Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
Trial Timeline
Nov 1, 2013 → Oct 1, 2014
NCT ID
NCT01791192About FTY720 + Oral Corticosteroid
FTY720 + Oral Corticosteroid is a phase 2 stage product being developed by Novartis for Acute Noninfectious Posterior, Intermediate, or Pan Uveitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01791192. Target conditions include Acute Noninfectious Posterior, Intermediate, or Pan Uveitis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Noninfectious Posterior, Intermediate, or Pan Uveitis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01791192 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Acute Noninfectious Posterior, Intermediate, or Pan Uveitis